An overview of binimetinib for the treatment of melanoma |
| |
| Authors: | Pol Specenier |
| |
| Affiliation: | 1. Department of Oncology, Antwerp University Hospital , Edegem, Belgium;2. Faculty of Health Sciences en Medicine, University of Antwerp , Antwerp, Belgium pol.specenier@uza.be |
| |
| Abstract: | ABSTRACT Introduction Approximately 50% of patients with metastatic melanoma have mutations in BRAF. Based on the results of prior phase III trials, the combination of a BRAF inhibitor (BRAFi) and a MEK inhibitor (MEKi) is the standard of care in patients with BRAF-mutant metastatic melanoma. |
| |
| Keywords: | Binimetinib BRAF NRAS melanoma MEK metastatic |
|
|
